Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  5. Curaleaf Holdings, Inc.
  6. News
  7. Summary
    CURA   CA23126M1023


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Curaleaf Holdings, Inc. : Target to become one of the world’s leading cannabis company

07/10/2020 | 05:12am EDT

An unorthodox pick among MarketScreener's selected opportunities, Curaleaf Holdings, formerly known as Lead Ventures Inc, is the sixth most valuable cannabis company in North America.

Albeit listed in Canada, the company operates essentially in the U.S. Of note are the peculiar backgrounds of its chairman — the Russian-American businessman Boris Jordan, a star investment banker known to advise oligarchs — and of its majority shareholder, Andrei Blokh, a former partner of Roman Abramovich.


Established in 2010, the company's financial history remains opaque till 2016, as its first public equity raise dates from 2018. Two highlights however: the company is still losing money — with a cash-burn before acquisitions of about $170mil — and it will require more capital to fulfill management's vision of becoming "the world’s leading cannabis company".

Of course, a substantial market opportunity shines in the horizon. While the U.S. legal cannabis industry is projected to total $16bn in 2020, total cannabis demand is estimated to total $75B-$100B, including markets serviced by illicit actors. 37 states have already legalized medical cannabis, and 12 out of these 37 have allowed adult-use for recreative ends. 

So far most of Curaleaf's efforts have focused on securing cultivating and processing license — costs and requirements vary by states — as well as acquiring peers across the value chain, from distribution to manufacturing. Growth of consumption per capita as new product forms, such as edibles and vapes, lead to proliferation of uses; building up a comprehensive offering takes time and money.

Management believes that vertical integration will distinguish Curaleaf from peers in their race to scale. Channel ownership burdens the cost structure, but it undercuts the middlemen — a rewarding feature in what should remain a high-margin retail segment — and enables products to reach consumers faster. In frontier markets, speed drives control.

Last year, the takeover of Grassroots propped the store count up to 135 venues, while the buyout of Select earlier in 2020 expanded wholesale to more than a thousand stores. With 2.2 million square feet of cultivation capacity, 180,000 patients served and 30 processing facilities, Curaleaf sports an unparalleled cost-to-coast footprint and ranks as a serious contender.

Despite the onset of the COVID-19 pandemic — or perhaps because of it — and thanks to these acquisitions, Curaleaf succeeded at growing revenue by 29% and adjusted EBITDA by 45% sequentially in 1Q20. It has also captured sizeable market shares in key states such as New Jersey or Florida, for a 14% market share nationwide.

Regardless, analysts see the integration of Grassroots as well as the expansion of regulated markets and conversion of illicit markets as major catalysts going forward. With $155mil in pro forma revenue, Curaleaf should widen the gap with its two closest followers, GTI and Trulieve, each with approximately $100mil in revenue.

Valuation-wise, shares trade at bubble-like PE ratios — a la Tesla, Netflix, etc. — but surprisingly affordable EBITDA multiples related to enterprise value, notwithstanding the fact that Curaleaf represents an ideal acquisition candidate for heavyweights such as Aurora, Canopy or GW Pharmaceuticals.

Value investors will look elsewhere, of course, but growth enthusiasts and momentum players may be keenly interested in following the next move. At this point, the key risks are an investor retreat — for instance if the pot rush came to fade — and the federal Department of Justice taking a closer look at cannabis M&A transactions.

Curaleaf is a position in Marketscreener's US portfolio.

© MarketScreener.com 2020
Stocks mentioned in the article
ChangeLast1st jan.
CRONOS GROUP INC. 0.57% 10.6 Delayed Quote.19.91%
CURALEAF HOLDINGS, INC. 0.18% 16.8 Delayed Quote.10.24%
ORGANIGRAM HOLDINGS INC. 0.53% 3.76 Delayed Quote.122.49%
06/08Update on Piper Sandler Hosted Cannabis Management Teams; 4th of 4 parts
06/08Update on Piper Sandler Hosted Cannabis Management Teams; 3rd of 4 parts
06/08Update on Piper Sandler Hosted Cannabis Management Teams; 2nd of 4 parts
06/08Piper Sandler Hosted Cannabis Management Teams; Finds US Outlook "Remains Rob..
06/08CURALEAF  : Select Brand And Rolling Stone Announce Strategic Partnership
06/08CURALEAF HOLDINGS BRIEF : Items Will Be Branded as 'Rolling Stone by Select' Whi..
06/08CURALEAF HOLDINGS BRIEF : Says Joining With Media Company, Rolling Stone, To Rol..
05/27CURALEAF  : Announces June Investor Community Conference and Event Participation
05/18CURALEAF  : to Acquire Colorado-based Los Suenos
05/17GRAIN HIGHLIGHTS : Top Stories of the Day
More news
Surperformance Ratings©
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
Yield -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Key data
Capitalization (CAD)
11 809 817 796
Capitalization (USD)
9 566 246 099
Net sales (USD)
626 637 000
Free-Float capitalization (CAD)
6 841 370 355
Free-Float capitalization (USD)
5 541 680 118
Avg. Exchange 20 sessions (USD)
4 452 297
Average Daily Capital Traded
Income Statement Evolution
EPS & Dividend
EPS Revisions
Revenue Revisions
Mean consensus BUY
Number of Analysts 16
Average target price 22,06 $
Last Close Price 13,61 $
Spread / Highest target 107%
Spread / Average Target 62,1%
Spread / Lowest Target 21,6%
Consensus revision (last 18 months)